RXRX FY2025 SEC EDGAR DEF 14A #98 of 168 in industry

Recursion Pharmaceuticals, Inc. CEO pay ratio

The CEO earned $9.5M in FY2025 against median worker pay of $287,986 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-30
Industry
Chemicals & Pharmaceuticals
Industry rank
#98/168

Data updated August 2026

Subscribe to Recursion Pharmaceuticals, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
33:1
Below Average (Scale: 0–1000:1)
CEO pay
$9.5M
Median worker
$287,986

Answer first

Recursion Pharmaceuticals, Inc.'s FY2025 CEO total of $9.5M ranks #564 of 1,423 complete filings; its 33:1 pay ratio ranks #1116. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $287,986. Industry placement uses the FY2025 SIC-28 peer cohort (# 98 of 168, 42nd percentile - below the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#564
$9.5M of 1,423 FY2025
Ratio rank
#1116
33:1 of 1,423
Industry pct
42nd
below the industry median pay ratio

How Recursion Pharmaceuticals, Inc. ranks nationally

Recursion Pharmaceuticals, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$9,503,538 Top 40% higher than 60% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). This entry sits in this band. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Recursion Pharmaceuticals, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($9.5M) against pay ratio (33:1) for Recursion Pharmaceuticals, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both02490794.94981589.87472384.79963179.630.4:133.5:136.5:139.5:142.5:1CEO total payPay ratio (CEO : median worker)Recursion Pharmaceuticals, Inc., CEO total pay: 9503538 · Pay ratio (CEO : median worker): 33:1Recursion Pharmaceuticals, Inc.Precigen, Inc., CEO total pay: 5354329 · Pay ratio (CEO : median worker): 34:1Precigen, Inc.Green Plains Inc., CEO total pay: 3642469 · Pay ratio (CEO : median worker): 31:1Green Plains Inc.Iovance Biotherapeutics, Inc., CEO total pay: 4755679 · Pay ratio (CEO : median worker): 31:1Iovance Biotherapeutics, Inc.Evolus, Inc., CEO total pay: 6412214 · Pay ratio (CEO : median worker): 35:1Evolus, Inc.Kiniksa Pharmaceuticals International, plc, CEO total pay: 310707 · Pay ratio (CEO : median worker): 35:1Kiniksa Pharmaceuticals International, plc
Recursion Pharmaceuticals, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Recursion Pharmaceuticals, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Recursion Pharmaceuticals, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2023–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
33:1
FY2025
vs prior FY
+5:1
from FY2024 28:1
CEO $ YoY
+13%
$9.5M latest
Filings shown
3
FY2023–2025
Recursion Pharmaceuticals, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2023 $8.5M - $243,069 35:1 -
2024 $8.4M -0.9% $300,991 28:1 -7:1
2025 $9.5M +13% $287,986 33:1 +5:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1601830, FY2023–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
33:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$9.5M
Companies in Industry
168
vs. Industry Median
Below
#98 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Recursion Pharmaceuticals, Inc.: MODEST · HEAVY pay ratio

Recursion Pharmaceuticals, Inc.'s 33:1 ratio ranks #1116 of 1,423 FY2025 complete filings (lower third by ratio). the CEO earned 33× the median employee ($287,986) in FY2025.

Median employee $287,986 (ELITE-MED); MODEST · HEAVY stamps put about 33 median-wage years per CEO year.

CEO Total Pay

$9.5M

FY2025 Summary Compensation, above median

Pay Ratio

33:1

Below typical

Recursion Pharmaceuticals, Inc. in the lower-ratio third

Recursion Pharmaceuticals, Inc.'s 33:1 ratio ranks #1116 of 1,423 FY2025 complete filings (lower third by ratio). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Recursion Pharmaceuticals, Inc.'s $9.5M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #564 and ratio rank #1116 split - treat 33:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$9.5M
Median Employee Pay
$287,986
Pay Ratio
33:1
Filing Date
2026-04-30

Company Info

Ticker
RXRX
CIK
1601830
Industry
Chemicals & Pharmaceuticals
SIC Code
2836
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1601830, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Recursion Pharmaceuticals, Inc.'s 33:1 ratio ranks #1116 of 1,423 FY2025 complete filings (lower third by ratio).

Read with Recursion Pharmaceuticals, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.

Rambus Inc · HEAVY

ABS(ceo_total_comp) peer at $9.5M (Δ $4K heavier vs Recursion Pharmaceuticals, Inc.); MODEST · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Graco Inc · HEAVY

ABS(ceo_total_comp) peer at $9.5M (Δ $12K lighter vs Recursion Pharmaceuticals, Inc.); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Cushman & Wakefield Ltd. · HEAVY

ABS(ceo_total_comp) peer at $9.5M (Δ $19K lighter vs Recursion Pharmaceuticals, Inc.); STEEP · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Eastgroup Properties Inc · HEAVY

ABS(ceo_total_comp) peer at $9.5M (Δ $29K lighter vs Recursion Pharmaceuticals, Inc.); MODEST · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Precigen, Inc. (SIC 28 pole)

Precigen, Inc. stamps MODEST · MID$ nearest in-SIC by ABS(pay_ratio) to Recursion Pharmaceuticals, Inc.'s MODEST filing.
National dual ranks · #564/#1116

Recursion Pharmaceuticals, Inc.'s FY2025 package sits #564 by CEO dollars and #1116 by ratio under HEAVY · MODEST.
Ratio primer · MODEST

Recursion Pharmaceuticals, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Recursion Pharmaceuticals, Inc. (CIK 1601830), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.